Interferon alfa-2a plus tretinoin in patients with metastatic renal cell carcinoma: A pilot study

American Journal of Health-System Pharmacy

Volumn 54, Issue 2, 1997, Pages 190-192

  Paule, Bernard ^a   Bonhomme Faivre, Laurence ^b   Rudant, Eric ^b   Ferrière, Francoise ^c  

^a Serv of Blood Disorders and Tumors   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN; INTERLEUKIN 6; RECOMBINANT ALPHA2A INTERFERON; RETINOIC ACID;

ADULT; AGED; ANOREXIA; CHEILITIS; CLINICAL ARTICLE; CONJUNCTIVITIS; DRUG CAPSULE; DRY SKIN; FATIGUE; FEMALE; FEVER; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY CARCINOMA; MALE; METASTASIS; NOTE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 1842407822     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.2.190     Document Type: Note

References (17)

1. Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol. 1987; 13(suppl 2):36-42.
2. Bollag W, Peck R. Cancer chemotherapy by combinations of retinoids with cytokines and vitamin D analogs. Experimental and clinical results. Ann Oncol. 1994; 5(suppl 9):S17-22.
3. Marth C, Daxenbichler G, Dapunt O et al. Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured renal cancer cells. J Natl Cancer Inst. 1986; 77:1197-202.
4. Frey JR, Peck R, Bollag W et al. Antiproliferative activity of retinoids, interferon alfa and their combination in five human transformed cell lines. Cancer Lett. 1991; 57:223-7.
5. Namus DM, Bogenrieder T, Engeister D et al. Analysis of retinoid receptors (RAR) and retinoid induced antiproliferative effects alone and in combination with interferon alfa in a human renal cancer. Aberrant RAR alfa transcript in a retinoid resistant cell line. Proc Am Assoc Cancer Res. 1994; 35:507. Abstract.
6. Muindi J, Frankel SR, Miller WJ Jr et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentration. Implications for relapse and retinoid resistance in patient with acute promyelocyte leukemia. Blood. 1992; 79:229-303.
7. Gribb AE, Renton KW. Dissociation of xanthine oxydase induction and cytochrome P450 depression during interferon induction in the rat. Biochem Pharmacol 1993; 3:2114-7.
8. Blay JY, Negrier S, Combaret V et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992; 52:3317-22.
9. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer. 1981; 47:207-14.
10. Montero-Julian FA, Liautard J, Flavetta S et al. Immunoassay for functional human soluble interleukin-6 receptor in plasma based on ligand/receptor interactions. J Immunol Methods. 1994; 169:111-21.
11. Darnell JE Jr, Kerr IM, Stark GR. jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signalling proteins. Science. 1994; 264:1415-20.
12. Motzer RJ, Murray-Law T, Schwartz P et al. Antitumoral activity of interferon alfa 2a and 13 cis retinoic acid (cRA) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 1994; 13:713. Abstract.
13. Bonhomme-Faivre L, Paule B, Urien S et al. Pharmacokinetics of all-trans retinoic acid (ATRA) in patients with renal cancer concomitantly treated with interferon alfa 2A (INF). Int J Pharm. 1996; 134:99-104.
14. Smith DC, Trump DL, Adedoyin A et al. Alterations in CYP2C mp activity induced by interferon α2a and all trans retinoic acid. Proc Am Assoc Cancer Res. 1994; 35:243. Abstract.
15. Pitot HC, Rubin J, Burch PB et al. Phase I study of all trans retinoic acid (NSC 122758) in solid tumors on an intermittent schedule. Proc Am Assoc Cancer Res. 1994; 35:245. Abstract.
16. Blay JY, Bolon I, Alberti L et al. Growth inhibition of renal carcinoma cell lines by interleukin 6 antisense oligonucleotides: an internal autocrine loop. Proc Am Assoc Cancer Res. 1994; 35:3667. Abstract.
17. Lee JS, Newman RA, Lippman SM et al. Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol. 1993; 11:959-66.